Evotec 2025 Outlook: Revenues To Grow 5%-10%, Reaching €840M-€880M (Vs. €879.457M Est.), Sees Adj. EBITDA Of €30M-€50M; For 2028 Outlook, Expects 8%-12% CAGR And An EBITDA Margin Above 20%

Benzinga
04-17

Guidance for full-year 2025

Group revenues expected in the range of € 840 - 880 m (2024: € 797.0 m)

R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.8 m)

Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m)

Outlook 2028

Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12 %

Adj. EBITDA margin 2028 expected to be above 20 %

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10